William Blair analyst Brandon Vazquez has maintained their neutral stance on MDT stock, giving a Hold rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Vazquez has given his Hold rating due to a combination of factors influencing Medtronic’s current financial and strategic position. While the company’s fiscal second-quarter sales and earnings per share exceeded expectations, these results were partly boosted by a one-time tax benefit and favorable foreign exchange impacts. The company’s cardiac ablation solutions, particularly the pulsed field ablation portfolio, have shown significant growth, but overall revenue growth remains in the mid-single digits.
Despite the promising developments in Medtronic’s pipeline, including advancements in renal denervation, diabetes products, and the anticipated U.S. launch of Hugo, the investments required have tempered potential earnings per share growth. Vazquez is cautious, seeking more consistent returns on investment from these initiatives before becoming more optimistic about the stock. With shares trading at 16 times fiscal 2026 earnings per share, he maintains a Market Perform rating, acknowledging the improving outlook but waiting for more tangible results from the company’s strategic efforts.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is neutral on the stock.